YPSOMED HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 411 CHF | +0.61% |
|
+4.45% | +35.64% |
| Jun. 20 | Ypsomed Partner Secures US FDA Nod for Automated Insulin Delivery Algorithm | MT |
| Jun. 12 | German Pharmaceutical Medac Picks Ypsomed Autoinjector for Methotrexate Pen Relaunch | MT |
| Sales 2025 * | 679M 752M | Sales 2026 * | 833M 923M | Capitalization | 5.61B 6.21B |
|---|---|---|---|---|---|
| Net income 2025 * | 116M 129M | Net income 2026 * | 176M 195M | EV / Sales 2025 * | 8.75 x |
| Net Debt 2025 * | 331M 366M | Net Debt 2026 * | 441M 489M | EV / Sales 2026 * | 7.26 x |
| P/E ratio 2025 * |
48.5
x | P/E ratio 2026 * |
31.9
x | Employees | 2,296 |
| Yield 2025 * |
0.64% | Yield 2026 * |
0.82% | Free-Float | 28.05% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ypsomed Holding AG
More recommendations
More press releases
More news
| 1 day | +0.61% | ||
| 1 week | +4.45% | ||
| Current month | +1.73% | ||
| 1 month | +7.59% | ||
| 3 months | +15.77% | ||
| 6 months | +35.64% | ||
| Current year | +35.64% |
1 week
402.00
417.50
1 month
381.50417.50
Current year
287.50417.50
1 year
243.50417.50
3 years
121.60417.50
5 years
102.40417.50
10 years
76.10417.50
| Managers | Title | Age | Since |
|---|---|---|---|
Simon Michel
CEO | Chief Executive Officer | 47 | 06-09-30 |
Frank Mengis
COO | Chief Operating Officer | 60 | 15-09-30 |
Thomas Kutt
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul R. Fonteyne
BRD | Director/Board Member | 62 | 17-12-31 |
| Director/Board Member | 54 | 18-12-31 | |
| Chairman | 60 | 20-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 10 M€ | -3.35% | - | |
| 0.01% | 775 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 411 | +0.61% | 17,058 |
| 24-07-02 | 408.5 | +0.12% | 12,387 |
| 24-07-01 | 408 | +0.99% | 18,650 |
| 24-06-28 | 404 | -1.94% | 19,654 |
| 24-06-27 | 412 | +0.24% | 19,499 |
Delayed Quote Swiss Exchange, July 03, 2024 at 11:30 am EDT
More quotes
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.
Calendar
2024-11-04
- Q2 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
408.5
CHF
Average target price
378
CHF
Spread / Average Target
-7.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +35.64% | 6.17B | |
| -7.03% | 180B | |
| -6.32% | 99.21B | |
| -6.15% | 66.25B | |
| -10.62% | 44.74B | |
| +8.34% | 43.82B | |
| +10.35% | 41.96B | |
| +11.64% | 28.98B | |
| +16.18% | 24.07B | |
| -8.87% | 23.5B |
- Stock Market
- Equities
- YPSN Stock
